Septapeptides associated with neurodegeneracy
AssigneeSepta Therapeutics, Inc.
InventorDiane VAN ALSTYNE
Life of this patent
Estimating the term…
Abstract
Methods and compositions useful in treating neurodegenerative disorders are based on septapeptides and extended forms thereof (or portions thereof) that exhibit chemokine activity with respect to microglial cell precursors.
Claims14
1-5. (canceled)
A method to identify an agent that blocks the monocyte chemoattractant protein-1 (MCP-1) receptor on microglia precursor cells which method comprises measuring the response of microglia precursor cells or stem cells to a septapeptide, an extended form thereof or binding portion thereof or extended form of said binding portion in the presence and absence of a candidate agent, wherein a candidate agent that diminishes the response of said cells to the septapeptide or portion or extended form thereof is identified as an agent that blocks the monocyte chemoattractant protein-1 (MCP-1) receptor on microglia precursor cells.
A method to identify an agent that blocks the monocyte chemoattractant protein-1 (MCP-1) receptor on microglia precursor cells which method comprises contacting a candidate agent with a septapeptide or an extended form thereof and determining the presence or absence of any complex formed, whereby a candidate agent that forms said complex is identified as an agent that blocks the monocyte chemoattractant protein-1 (MCP-1) receptor on microglia precursor cells.
14-27. (canceled)
Dependencies are inferred from the claim text.